Urate-lowering therapy and risk of cardiorenal mortality in patients with type 2 diabetes and asymptomatic hyperuricemia
Main finding · Cardiorenal mortalityResult — go to the resultHazard ratio 0.66 95 % CI 0.52–0.83Authors' conclusion
In patients with T2DM and asymptomatic HUA, ULT use was associated with a significant reduction in cardiorenal and all-cause mortality. These findings highlight a potential role for ULT in the broader context of cardiometabolic risk management, beyond its traditional use for gout prevention.
Study context
- Population
- Adults with T2D and asymptomatic hyperuricemia, electronic health records in Taiwan, 2016–2021after matching
- Participants
- 2,534 adults
- Exposure
- Urate-lowering therapy (ULT) vs no ULT
- Outcome
- Cardiorenal mortality
- Follow-up
- Mean 3.4 years
Methodological detailsmulticenter, propensity score matching, prescription time-distribution matching
- Multicenter
- Propensity score matching
- Prescription time-distribution matching
Main finding
As reported in the abstract
Hazard ratio
0.66
95 % CI 0.52–0.83
ULTvs Untreated
HR 0.66 (95 % CI 0.52–0.83)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| All-cause mortality · mean follow-up 3.4 yearsMatched cohort | 0.71 (0.62–0.80) | |
| 0.512Hazard ratio (log scale) |
Sensitivity analyses
- Sensitivity analyses yielded consistent findings across multiple models
Original publication
Urate-lowering therapy and risk of cardiorenal mortality in patients with type 2 diabetes and asymptomatic hyperuricemia. Diabetes Res Clin Pract. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →